NR4A1 and breast cancer: The OncotypeDX® 21- gene expression assay (Genomic health, Redwood City, CA) is prognostic and predictive of benefit from adjuvant chemotherapy (aCT) for women with hormone receptor-positive (HR +) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (BC) [1–3].